Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom

Inflammatory Bowel Disease

Efficacy, tolerability and safety of low volume bowel preparations in Inflammatory Bowel Diseases: The French multicentre CLEAN study

J Crohns Colitis.

Briot C, Faure P, Parmentier AL, Nachury M, Trang C, Viennot S, Altwegg R, Bulois P, Thomassin L, Serrero M, Ah-Soune P, Gilletta C, Plastaras L, Simon M, Dray X, Caillo L, Del Tedesco E, Abitbol V, Zallot C, Degand T, Rossi V, Bonnaud G, Colin D, Morel B, Winkfield B, Danset JB, Filippi J, Amiot A, Attar A, Levy J, Peyrin-Biroulet L, Vuitton L; CLEAN study group

doi: 10.1093/ecco-jcc/jjz040.

Inflammatory Bowel Disease

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Inflamm Bowel Dis.

Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, Glover SC, Zimmermann EM

doi: 10.1093/ibd/izz001.

Inflammatory Bowel Disease

Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort

Eur J Gastroenterol Hepatol.

Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM, Swiss IBD Cohort Study Group

doi: 10.1097/MEG.

Inflammatory Bowel Disease

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Therap Adv Gastroenterol.

Grob L, Bluemel S, Biedermann L, Fournier N, Rossel JB, Vavricka SR, Zeitz J, Rogler G, Stallmach A, Scharl M

doi: 10.1177/1756284819895217.

Inflammatory Bowel Disease

Causes of Treatment Failure In Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study

J Pediatr Gastroenterol Nutr.

Naviglio S, Lacorte D, Lucafò M, Cifù A, Favretto D, Cuzzoni E, Silvestri T, Pozzi Mucelli M, Radillo O, Decorti G, Fabris M, Bramuzzo M, Taddio A, Stocco G, Alvisi P, Ventura A, Martelossi S

doi: 10.1097/MPG.

RECOMMENDED

Inflammatory Bowel Disease

Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort - an Epi-IBD study

doi: 10.1111/jgh.14563.

Inflammatory Bowel Disease

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

United European Gastroenterol J.

Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A

doi: 10.1177/2050640620929133.

Inflammatory Bowel Disease

Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)

Eur J Clin Microbiol Infect Dis.

Vehreschild MJGT, Taori S, Goldenberg SD, Thalhammer F, Bouza E, van Oene J, Wetherill G, Georgopali A

doi: 10.1007/s10096-018-3344-1.

Inflammatory Bowel Disease

Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases

Clin Gastroenterol Hepatol.

Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV Jr, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS

doi: 10.1016/j.cgh.2018.09.035.

Related content

Efficacy, tolerability and safety of low volume bowel preparations in Inflammatory Bowel Diseases: The French multicentre CLEAN study

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Causes of Treatment Failure In Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study

Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort - an Epi-IBD study

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)

Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases